COMP <GO>
PHVS vs NAMS // EV/EBITDA & P/E VALUATION
Pharvaris N.V. (NASDAQ) VS. NewAmsterdam Pharma Company N.V. (NASDAQ) • 15-METRIC TALLY: PHVS 1
— NAMS 1
■ METRIC PARITY
LAST: $33.53 (0.00%) • MKT CAP: $2.34B
valuation
—
LAST: $19.56 (-2.49%) • MKT CAP: $2.40B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PHVS VS. NAMS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PHVS | NAMS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -5.96% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -50.60% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 15.94 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 3/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.4 | 41.9 | +17.50 | PHVS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.34B | $2.40B | -$62.0M | NAMS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PHVS REV | NAMS REV | PHVS GROSS % | NAMS GROSS % | PHVS FCF | NAMS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $22.5M | — | — | — | -$147.8M |
| FY 2024 | — | $45.6M | — | — | — | -$158.6M |
| FY 2023 | — | $14.1M | — | — | — | -$141.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PHVS // BETA —
NAMS // BETA —